Brain metastasis and response to ado-trastuzumab emtansine: A case report and literature review

Clinical Breast Cancer

Volumn 15, Issue 2, 2015, Pages e163-e166

  Kalsi, Richa ^a   Feigenberg, Steven ^a   Kwok, Young ^a   Tkaczuk, Katherine ^a   Mehta, Minesh ^a   Chumsri, Saranya ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Ado trastuzumab emtansine; CNS metastasis; HER2; Lapatinib; Radiation

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ERIBULIN; ESTROGEN RECEPTOR; FULVESTRANT; GEMCITABINE; IXABEPILONE; KI 67 ANTIGEN; LAPATINIB; NAVELBINE; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VORINOSTAT; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN STEM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CEREBELLUM; CEREBELLUM INJURY; DRUG APPROVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; FRAMELESS STEREOTACTIC PROCEDURE; HEMISPHERE; HUMAN; LYMPH NODE; LYMPHEDEMA; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; INFLAMMATORY BREAST CANCER; PATHOLOGY; PROCEDURES; SALVAGE THERAPY; SECONDARY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MAYTANSINE; SALVAGE THERAPY;

EID: 84924905965     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.10.003     Document Type: Article

References (27)

1. P.E. Goss, S. Qi, and R.G. Josse The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats Bone 34 2004 384 392
2. P.E. Goss, S. Qi, A.M. Cheung, H. Hu, M. Mendes, and K.P. Pritzker Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats Clin Cancer Res 10 2004 5717 5723
3. A.J. Clayton, S. Danson, and S. Jolly Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 2004 639 643
4. J.C. Bendell, S.M. Domchek, and H.J. Burstein Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2003 2972 2977
5. S. Verma, D. Miles, and L. Gianni Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791
6. S.A. Hurvitz, L. Dirix, and J. Kocsis Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer J Clin Oncol 31 2013 1157 1163
7. P.B. Larsen, I. Kumler, and D.L. Nielsen A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer Cancer Treat Rev 39 2013 720 727
8. N.U. Lin Breast cancer brain metastases: new directions in systemic therapy Ecancermedicalscience 7 2013 307
9. H.J. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck, and V. Heinemann Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anticancer Drugs 18 2007 23 28
10. B. Gril, D. Palmieri, and J.L. Bronder Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J Natl Cancer Inst 100 2008 1092 1103
11. N.U. Lin, L.A. Carey, and M.C. Liu Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 2008 1993 1999
12. N.U. Lin, V. Dieras, and D. Paul Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 2009 1452 1459
13. + breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) ( 1094) J Clin Oncol 26 2008 1094
14. G. Metro, J. Foglietta, and M. Russillo Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine Ann Oncol 22 2011 625 630
15. S. Sutherland, S. Ashley, and D. Miles Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience Br J Cancer 102 2010 995 1002
16. T. Bachelot, G. Romieu, and M. Campone Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Lancet Oncol 14 2013 64 71
17. N.U. Lin, W. Eierman, and R. Greil Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases J Neurooncol 105 2011 613 620
18. C. Platini Trastuzumab and blood-brain barrier [in French] Bull Cancer 94 2007 857 859
19. R. Bartsch, A. Rottenfusser, and C. Wenzel Trastuzumab prolongs overall survival in patients with brain metastases from HER2-positive breast cancer J Neurooncol 85 2007 311 317
20. D.N. Church, R. Modgil, and S. Guglani Extended survival in women with brain metastases from HER2 overexpressing breast cancer Am J Clin Oncol 31 2008 250 254
21. R. Le Scodan, L. Jouanneau, and C. Massard Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death BMC Cancer 11 2011 395
22. G. Metro, I. Sperduti, M. Russillo, M. Milella, F. Cognetti, and A. Fabi Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer Oncologist 12 2007 1467 1469 author reply 9-71
23. I.H. Park, J. Ro, K.S. Lee, B.H. Nam, Y. Kwon, and K.H. Shin Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer Ann Oncol 20 2009 56 62
24. Y.H. Park, M.J. Park, and S.H. Ji Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients Br J Cancer 100 2009 894 900
25. + metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC). ESMO Annual Meeting 2012; LBA11.
26. M.J. Ellis, A. Coop, and B. Singh Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status Cancer Res 63 2003 6523 6531
27. R. Bartsch, A.S. Berghoff, and M. Preusser Breast cancer brain metastases responding to primary systemic therapy with T-DM1 J Neurooncol 116 2014 205 206